RenovoRx, Inc.: RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
RenovoRx (Nasdaq: RNXT) said it has completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer. Trial enrollment is closing as of Aug. 7, 2026, with completion expected in 1H 2027 after 86 deaths events, and 78 events reported as of Aug. 11. Initial top-line data is expected in 2H 2027; primary endpoint is overall survival.
How this was made
The 30-second read
Why it matters
Completion of enrollment is a meaningful execution milestone for the Phase III TIGeR-PaC trial, shifting focus to event accumulation (86 deaths) and eventual overall survival top-line data in 2H 2027.
Market read
Traders can update RNXT’s clinical timeline and probability-weighted risk profile based on enrollment closure and the remaining event count to the primary endpoint.
What to watch
The article does not provide interim efficacy metrics, safety signals, or event-rate expectations beyond the event count, so timing risk to the 2027 readout remains.
Background
RenovoRx is developing a drug-device combination using its FDA-cleared RenovoCath device to deliver intra-arterial gemcitabine via its TAMP platform in locally advanced pancreatic cancer.
Ticker impact
RenovoRx says Phase III TIGeR-PaC enrollment is complete, with 78 of 86 death events reached and top-line data expected in 2H 2027.
Near-term upside bias on execution milestone, with volatility likely to fade until interim signals or the 2H 2027 top-line readout.
The article provides a concrete operational milestone (closing enrollment) and a defined event-based timeline (86 events, 78 observed), which can move biotech risk perception even without efficacy results yet.
Market effects
Supports sentiment for drug-device oncology platforms and locoregional delivery approaches in pancreatic cancer.
Limited, primarily US biotech sentiment tied to Nasdaq-listed RNXT.
Moderate, as pancreatic cancer trial progress can influence global investor appetite for similar delivery technologies.
Counterpoint
Enrollment completion does not confirm efficacy; investors may discount the milestone until survival outcomes are reported after the 86-event threshold.
Key entities
- companyRenovoRx, Inc.
Nasdaq-listed life-sciences company developing targeted oncology therapies and commercializing RenovoCath.
- clinical_trialTIGeR-PaC trial
Phase III randomized multi-center trial in locally advanced pancreatic cancer with overall survival as the primary endpoint.
- medical_deviceRenovoCath
FDA-cleared drug-delivery device used for intra-arterial administration in the trial.
- therapyIntra-arterial gemcitabine (IAG)
Investigational drug-device combination candidate delivered via RenovoCath.
